SKYE

MKT CAP:$31M

Skye Bioscience, Inc.

Market Cap

$31M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$0.90+$0.02 (+2.48%)

Apr 22, 2026

Company Details

Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I trials fo...

CEO

Punit S. Dhillon

IPO Date

Nov 26, 2014

Website

skyebioscience.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$51M

EPS (Diluted)

-$1.28

Free Cash Flow

-$9.2B

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q4 2025

May 14, 2026

PENDING

FY 2025

Mar 10, 2026

$0EPS -$1.41

Q3 2025

Nov 10, 2025

$0EPS -$0.32

Q2 2025

Aug 7, 2025

$0EPS -$0.44

Q1 2025

May 8, 2025

$0EPS -$0.28

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q4 21	$0	$0	-$2M
Q1 22	$0	$0	-$3M
Q2 22	$0	$0	-$3M
Q3 22	$0	$0	-$3M
Q4 22	$0	$0	-$9M
Q1 23	$0	$0	-$3M
Q2 23	$0	$0	-$3M
Q3 23	$0	$0	-$25M
Q4 23	$0	$0	-$4M
Q1 24	$0	$0	-$6M
Q2 24	$0	$0	-$8M
Q3 24	$0	$0	-$5M
Q4 24	$0	$0	-$11M
Q1 25	$0	$0	-$12M
Q2 25	$0	$0	-$18M
Q3 25	$0	$0	-$13M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 21	-$2M	-$2M
Q1 22	-$3M	-$3M
Q2 22	-$3M	-$3M
Q3 22	-$2M	-$2M
Q4 22	-$5M	-$5M
Q1 23	-$4M	-$4M
Q2 23	-$2M	-$2M
Q3 23	-$4M	-$4M
Q4 23	-$4M	-$4M
Q1 24	-$5M	-$5M
Q2 24	-$7M	-$7M
Q3 24	-$5M	-$7M
Q4 24	-$8M	-$8M
Q1 25	-$9.2B	-$9.2B
Q2 25	-$11M	-$11M
Q3 25	-$13M	-$13M

Capital Expenditures

Quarter	CapEx
Q4 21	$54.0K
Q1 22	$2.0K
Q2 22	$3.2K
Q3 22	$10.3K
Q4 22	$79.0K
Q1 23	$1.9K
Q2 23	$0
Q3 23	$3.7K
Q4 23	$7.0K
Q1 24	$3.2K
Q2 24	$32.5K
Q3 24	$2M
Q4 24	$50.0K
Q1 25	$6M
Q2 25	$3
Q3 25	$5

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 21	—	+86.6%
Q1 22	—	+66.2%
Q2 22	—	+75.9%
Q3 22	—	+60.6%
Q4 22	—	+277.1%
Q1 23	—	+7.3%
Q2 23	—	-11.7%
Q3 23	—	+745.4%
Q4 23	—	-56.0%
Q1 24	—	+98.4%
Q2 24	—	+195.7%
Q3 24	—	-79.9%
Q4 24	—	+161.0%
Q1 25	—	+91.1%
Q2 25	—	+117.0%
Q3 25	—	+167.0%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 21	$122.0K	—
Q1 22	$137.4K	—
Q2 22	$144.4K	—
Q3 22	$144.1K	—
Q4 22	$203.2K	—
Q1 23	$131.6K	—
Q2 23	$102.9K	—
Q3 23	$160.2K	—
Q4 23	$592.9K	—
Q1 24	$2M	—
Q2 24	$2M	—
Q3 24	$2M	—
Q4 24	$2M	—
Q1 25	$2M	—
Q2 25	$2M	—
Q3 25	$2M	—

OpEx Breakdown

Quarter	R&D	G&A
Q4 21	$1M	$1M
Q1 22	$1M	$2M
Q2 22	$1M	$2M
Q3 22	$2M	$1M
Q4 22	$2M	$2M
Q1 23	$1M	$2M
Q2 23	$2M	$1M
Q3 23	$1M	$2M
Q4 23	$2M	$2M
Q1 24	$2M	$4M
Q2 24	$4M	$4M
Q3 24	$5M	$5M
Q4 24	$8M	$5M
Q1 25	$7M	$5M
Q2 25	$14M	$4M
Q3 25	$9M	$4M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$6M	$0	$6M
Q2 22	$3M	$0	$3M
Q3 22	$415.4K	$0	$415.4K
Q4 22	$1M	$0	$1M
Q1 23	$3M	$0	$3M
Q2 23	$553.4K	$0	$553.4K
Q3 23	$5M	$0	$5M
Q4 23	$1M	$0	$1M
Q1 24	$83M	$0	$83M
Q2 24	$74M	$0	$74M
Q3 24	$67M	$0	$67M
Q4 24	$68M	$0	$68M
Q1 25	$46M	$13M	$59M
Q2 25	$24M	$25M	$49M
Q3 25	$18M	$17M	$35M
Q4 25	$6M	$20M	$26M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q4 21	2M	-0.1%	+45.7%
Q1 22	2M	+19.8%	+47.2%
Q2 22	2M	+0.0%	+31.0%
Q3 22	2M	0.0%	+19.7%
Q4 22	3M	+26.7%	+51.8%
Q1 23	4M	+49.9%	+90.0%
Q2 23	4M	+3.1%	+95.9%
Q3 23	8M	+102.8%	+297.3%
Q4 23	12M	+56.7%	+391.4%
Q1 24	28M	+126.7%	+643.2%
Q2 24	39M	+38.1%	+895.0%
Q3 24	39M	+0.4%	+392.6%
Q4 24	40M	+3.0%	+223.7%
Q1 25	40M	-0.8%	+41.6%
Q2 25	40M	+0.0%	+2.6%
Q3 25	40M	+0.0%	+2.2%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q4 21	$0	9
Q1 22	$0	9
Q2 22	$0	9
Q3 22	$0	9
Q4 22	$0	9
Q1 23	$0	9
Q2 23	$0	9
Q3 23	$0	9
Q4 23	$0	11
Q1 24	$0	11
Q2 24	$0	11
Q3 24	$0	11
Q4 24	$0	16
Q1 25	$0	16
Q2 25	$0	16
Q3 25	$0	16

Revenue / Employee